ArticleJournal of virology2025
ARRDC1 inhibits the replication of Semliki Forest virus by regulating the ubiquitination and degradation of viral nsP4.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RNAViruses · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Alphavirus infection can result in a spectrum of clinical manifestations in the host, including fever, rash, arthritis, and even symptoms of encephalitis, thereby posing a severe threat to global public health security. In this study, we explored the role of arrestin domain-containing protein 1 (ARRDC1) in the replication of Semliki Forest virus (SFV), an important member of alphaviruses, by siRNA-based knockdown or CRISPR/Cas9-mediated knockout techniques. SFV replication levels are significantly increased by knockdown or knockout of ARRDC1 in multiple cell lines and inhibited by trans-complementation with ARRDC1. Our data further revealed that ARRDC1 affects the early RNA replication stage of SFV. The antiviral effect of ARRDC1 is dependent on its cell plasma membrane localization and ubiquitin ligase binding motif. Mechanistically, ARRDC1 binds to viral nonstructural protein 4 (nsP4) and facilitates its degradation by the ubiquitination pathway, thereby blocking the replication of SFV. In summary, this work identifies ARRDC1 as a novel restriction factor of SFV, potentially advancing the development of novel strategies against alphavirus infection.IMPORTANCESemliki Forest virus (SFV) belongs to the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.